Skip to main content
ACTU logo

Actuate Therapeutics Inc (ACTU) Stock Price & Analysis

Actuate Therapeutics Inc (ACTU) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.2138 (-12.95%), as of the Nov 19, 2026 trading session; market cap $12.9M.

Educational signal · not a buy or sell recommendation · How to read this

$0.2138 −$0.0318 (-12.95%) Market Cap $12.9M

Actuate Therapeutics Inc · ACTU · NASDAQ

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment. Their lead product, Elraglusib Injection, targets metastatic pancreatic ductal adenocarcinoma and other cancers.

Price as of Nov 19, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Actuate Therapeutics (ACTU)

Weak
Business Quality Thin (34)
Financial Safety Fragile (10)
Valuation Bubble (0)
Growth Durability Flat (51)
Momentum Falling (13)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a fragile balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Falling.

Earnings yield is the main valuation drag relative to sector peers.

  • EPS beat 4 of the last 8 reports

Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ACTU (57 recorded, newest six shown)
RecordedScoreBand
26Weak
26Weak
27Weak
27Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.2138
Change on the day-12.95%
52-week range$0.2138 – $7.90
Market capitalisation$12.9M—
Shares traded on the day2.99M

Price & events

Other perspectives

Council score for Actuate Therapeutics (ACTU): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Negative
Growth Durability Neutral
Momentum Negative

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Gross Margin Negative

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Actuate Therapeutics (ACTU), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Actuate Therapeutics Inc (ACTU) is listed on NASDAQ. It employs 12 people and is led by Daniel Schmitt. The market values it at $12.9M.

2 · Latest results

What do the latest results show for Actuate Therapeutics (ACTU)?

Short answer · as of

Against analyst estimates the company has EPS beat 4 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Actuate Therapeutics (ACTU)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 0.73.

Data-derived red flags

  • Listing risk — at $0.2138 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Actuate Therapeutics (ACTU)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $0.00 · EPS -0.64 · 0 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for ACTU.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Actuate Therapeutics compare with its peers?

Short answer

Actuate Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Named competitor$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
Actuate Therapeutics (ACTU) — this page$0.2138$12.9M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$0.00
EPS estimate
$-0.64

Measured against a quoted price of $0.2138 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 28, 2026

Transactions
35
Identified insiders
4
Purchases
2
Sales
0
Other transactions
33

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ACTU in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ACTU in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Actuate Therapeutics (ACTU)?

Read these with our analysis →

Actuate Therapeutics Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the ACTU research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ACTU?

ACTU carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment.

Is ACTU a good stock to buy?

Stock Expert AI does not rate ACTU buy, sell or hold. Actuate Therapeutics Inc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ACTU stock price today?

The last price recorded for Actuate Therapeutics Inc (ACTU), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ACTU?

Actuate Therapeutics faces several key risks inherent to its business model and industry. The primary risk is the potential failure of Elraglusib in clinical trials, which would significantly impact the company's value.

What are the key factors to evaluate for ACTU?

Actuate Therapeutics Inc (ACTU) holds a MoonshotScore in the low range. This strategy could be implemented at any time, depending on clinical trial progress and market interest. Not financial advice.

How frequently does ACTU data refresh on this page?

ACTU's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ACTU's recent stock price performance?

Actuate Therapeutics Inc (ACTU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ACTU overvalued or undervalued right now?

Actuate Therapeutics Inc (ACTU) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ACTU?

Fractional-share availability for Actuate Therapeutics Inc (ACTU) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 5 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.